Clozapine-induced neutropenia in children: management with lithium carbonate.

@article{Sporn2003ClozapineinducedNI,
  title={Clozapine-induced neutropenia in children: management with lithium carbonate.},
  author={Alexandra L. Sporn and Nitin Gogtay and Roberto Ortiz-Aguayo and Cara L. Alfaro and Julia W. Tossell and Marge C. Lenane and Peter A. Gochman and Judith L. Rapoport},
  journal={Journal of child and adolescent psychopharmacology},
  year={2003},
  volume={13 3},
  pages={
          401-4
        }
}
Clozapine, an atypical antipsychotic, is the most effective medication for treatment-resistant schizophrenia, but its use is limited by the high risk of neutropenia and agranulocytosis. In children, the rate of clozapine-induced neutropenia is even higher than in adults. We report two cases of children 7- and 12-years old diagnosed with very early onset schizophrenia, who developed neutropenia when treated with clozapine. In both cases addition of lithium carbonate elevated the white blood… Expand
Continuing clozapine treatment despite neutropenia
TLDR
Although the procedures adopted in the cases described in this review are uncommon, they potentially provide an alternative to the discontinuation of clozapine treatment in patients with complex symptomatologies for whom treatment with other antipsychotic medication is insufficient. Expand
Managing clozapine-induced neutropenia with lithium
TLDR
The efficacy and safety of lithium augmentation for the management of clozapine-induced neutropenia is reviewed and it is found that lithium may be useful in raising the WBC in patients whose baseline count is too low to allow treatment with clozAPine to start and to protect against clozapsania, thus allowing more patients to benefit from treatment withClozapines. Expand
Late-onset clozapine-induced neutropenia treated with lithium
  • P. T. Durmus
  • Medicine
  • Dusunen Adam: The Journal of Psychiatry and Neurological Sciences
  • 2019
TLDR
A case of clozapine-induced neutropenia in a schizophrenic patient seen after 7 years of clazapine use and its treatment with lithium supplementation is presented. Expand
Adjunctive use of lithium carbonate for the management of neutropenia in clozapine‐treated children
TLDR
The use of lithium to manage neutropenia in childhood‐onset schizophrenia (COS) through a systematic audit of COS cases is explored. Expand
Restarting Clozapine after Neutropenia
TLDR
Uncertainty over the likely cause of blood dyscrasia in people taking clozapine, coupled with uncertainty over the mechanism by which clozabine causes both neutropenia and agranulocytosis, makes any attempt to restart clozAPine a high-risk venture requiring the utmost caution. Expand
Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.
TLDR
The study shows that the rates of neutropenia in clozapine-treated children and adolescents are considerably higher than in the adult population. Expand
Clozapine-induced leukopenia successfully treated with lithium.
TLDR
A 55-year-old man with paranoid schizophrenia who had been stable on clozapine for more than 10 years was admitted to an inpatient behavioral health unit with leukopenia associated with clozAPine use and lithium was used to stimulate leukocyte production. Expand
Hematological adverse events in clozapine-treated children and adolescents.
TLDR
The occurrence of HAEs is a significant risk associated with the administration of clozapine, but in this sample, few children actually discontinued therapy because of an HAE and the incidence of agranulocytosis does not appear higher than what has been reported in the adult literature. Expand
Haematological toxicity of clozapine and some other drugs used in psychiatry
TLDR
To review recent work on the haematological toxicity of clozapine and some other drugs used in psychiatry, the mechanism of antipsychotic‐induced neutropenia/agranulocytosis is reviewed and safety concerns regarding clozAPine in children/adolescents are reviewed. Expand
Clozapine use in children and adolescents
TLDR
Despite a higher incidence of adverse effects in children, clozapine appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Continuing clozapine treatment despite neutropenia
TLDR
Although the procedures adopted in the cases described in this review are uncommon, they potentially provide an alternative to the discontinuation of clozapine treatment in patients with complex symptomatologies for whom treatment with other antipsychotic medication is insufficient. Expand
Initiation of Clozapine Therapy in a Patient with Preexisting Leukopenia: A Discussion of the Rationale of Current Treatment Options
TLDR
The effectiveness of lithium in reversing CIG in a young man with preexisting mild granulocytopenia is reported and the rapidity of onset of leukocyte depletion is discussed in light of previously hypothesized autoimmune mechanisms of CIG. Expand
Lithium and clozapine-induced neutropenia/agranulocytosis.
TLDR
Lithium administration was used in a patient with a clozapine-induced neutropenia and in another with complete agranulocytosis to assess whether lithium could stimulate neutrophil production and in both cases, the neutrophIL count was increased to the normal range within 6 days. Expand
Circadian rhythm of white blood cells during clozapine treatment
TLDR
Some patients with refractory schizophrenia may have a spuriously low cell count and may be unnecessarily denied effective treatment, as behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC). Expand
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
TLDR
The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future. Expand
Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine.
TLDR
This case report is not intended to challenge the clinical practice of discontinuing clozapine upon the development of neutropenia/agranulocytosis, but to stimulate further research in the pathophysiology and clinical consequences of a clozAPine rechallenge after a WBC decline. Expand
Management of Schizophrenia in Children and Adolescents
TLDR
The main advantages of clozapine treatment in this age group in comparison with typical antipsychotics are: high antipsychotic efficacy during an acute schizophrenic episode; better improvement in chronic cases with a high load of negative symptoms; and markedly fewer extrapyramidal adverse effects and, therefore, fairly good tolerability. Expand
Retreatment with clozapine after erythromycin-induced neutropenia.
TLDR
The case of a patient with refractoryschizophrenia who was retreated with clozapine several years after de-veloping neutropenia under unusual circumstances is illustrated and suggeststhat the interaction of clozAPine with erythromycin was theprecipitating factor for the patient’s blood dyscrasia. Expand
Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.
TLDR
The case register yielded valuable information for guiding research into the causes of the haematological reactions in subjects receiving clozapine, and the risk for agranulocytosis in Asian subjects was 2.4 times that in Caucasians. Expand
The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF).
TLDR
Until efficacy studies prove otherwise, G-CSF administered soon after the diagnosis of clozapine-associated agranulocytosis may shorten the duration of hospitalization and thus prove cost-effective. Expand
...
1
2
...